Clinical Trials Logo

Healthy Volunteers clinical trials

View clinical trials related to Healthy Volunteers.

Filter by:

NCT ID: NCT05350566 Completed - Healthy Volunteers Clinical Trials

Combined Effect of Exercise Intensity With Nutritional Supplementation on Skeletal Muscle Function

NUTSPORT
Start date: June 7, 2022
Phase: N/A
Study type: Interventional

The main objective of this study is to determine the effectiveness of a nutritional intervention (olive leaf extract) combined with a specific training session (MICT or SIT) on PDH activation (as well as other protein expressions) and exercise-induced muscle fatigue.

NCT ID: NCT05346601 Completed - Healthy Volunteers Clinical Trials

Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers

Start date: June 2, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to further study the pharmacokinetic characteristics of Chiauranib Capsule in Healthy Volunteers with High Fat Diet.

NCT ID: NCT05337345 Completed - Healthy Volunteers Clinical Trials

A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants

Start date: May 2, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug levels of cendakimab delivered subcutaneously in healthy participants.

NCT ID: NCT05323708 Completed - Healthy Volunteers Clinical Trials

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers: DENARIUS: DENosumab Pharmacokinetic equivAlence tRIal in Healthy volUnteerS

DENARIUS
Start date: March 9, 2022
Phase: Phase 1
Study type: Interventional

This study is to compare the Pharmacokinetics, Pharmacodynamics, safety, and tolerability of Bmab 1000 and Prolia® in normal healthy volunteers.

NCT ID: NCT05320861 Completed - Healthy Volunteers Clinical Trials

Single Dose ADME Study of [14C]SJP-0008 in Healthy Male Subjects

Start date: September 24, 2021
Phase: Phase 1
Study type: Interventional

This single centre, open-label, non-randomised, single period, single-dose study in healthy male subjects was designed and conducted to assess the mass balance recovery, PK, metabolite profile and metabolite identification of SJP-0008.

NCT ID: NCT05306106 Completed - Healthy Volunteers Clinical Trials

Glycemic Index of Pastry

IG-DESSERT
Start date: April 6, 2021
Phase: N/A
Study type: Interventional

In the early 1980s and following the first publications by Jenkins et al., The notion of glycemic index (GI) appeared with the aim of classifying the different sources of carbohydrates in our diet according to their effect on the post-prandial glycemic response. Since these years, many studies have been designed to determine the usefulness of the glycemic index and indicate that a low glycemic index for a food, a dish, a meal or a diet is associated with a decreased risk of metabolic pathologies (diabetes, hypertriglyceridemia), degenerative (cardiovascular diseases) or overload (obesity). This justifies the interest in favoring foods with a low glycemic index in healthy subjects. A review confirmed the mechanistic link between postprandial blood sugar and the variability of blood sugar, making it possible, on the one hand, to maintain good glucose homeostasis and, on the other hand, to prevent pathologies such as obesity, diabetes and cardio-vascular diseases. The EFSA also considers that reducing the increase in blood sugar in the post-meal phase can be considered a physiological benefit, especially in subjects with glucose intolerance. Post-meal blood sugar depends on many factors including the glycemic index of foods eaten during the meal. Knowing the glycemic index of foods is therefore very useful. Mademoiselle Dessert offers pastries with a low glycemic index. The objective of this study is thus to determine the glycemic index of 6 pastries in order to inform consumers on these pastries glycemic index.

NCT ID: NCT05305222 Completed - Healthy Volunteers Clinical Trials

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

Start date: October 23, 2017
Phase: Phase 1
Study type: Interventional

The main objective of this study is to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single intravenous (IV) infusion of risankizumab in healthy Japanese and Caucasian participants.

NCT ID: NCT05303220 Completed - Healthy Volunteers Clinical Trials

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Start date: April 8, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the relative bioavailability of branebrutinib tablet formulation relative to the capsule formulation in order to identify doses that would provide exposures similar to the capsule formulation over the dose range that may be used in future clinical studies, evaluate the effect of food on the bioavailability of branebrutinib from a tablet formulation at a dose projected to provide similar pharmacokinetics (PK) as the 9 mg capsule formulation, and evaluate the safety and the PK of multiple oral dose of tablet formulation of branebrutinib in healthy participants.

NCT ID: NCT05299073 Completed - Healthy Volunteers Clinical Trials

A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva

Start date: March 1, 2022
Phase: Phase 1
Study type: Interventional

Randomized, double blind, parallel group, single dose, 3 arm study to investigate and compare the PK, PD, safety and immunogenicity profile of MB09 with EU/US-Xgeva® in healthy male subjects. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Pharmacodynamics, safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.

NCT ID: NCT05298787 Completed - Healthy Volunteer Clinical Trials

A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program

Start date: January 13, 2021
Phase: Phase 1
Study type: Interventional

This is a Phase 1, single-center, randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety, tolerability, PK, and PD of single- and multiple-ascending doses of RLS-0071 in healthy adult subjects.